One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1182/blood-2021-146585
Copy DOI Journal: Blood |  Publication Date: Nov 5, 2021 |
 Citations: 3 |
Affiliation: The University of Texas MD Anderson Cancer Center, Harvard University, Beth Israel Deaconess Medical Center, Hospices Civils de Lyon, Dana-Farber Cancer Institute, University Hospital Münster, University of California, Irvine, Northwestern University, City of Hope, Moffitt Cancer Center, ImmunoGen (United States), Duke University, Istituto di Ematologia di Bologna, Roswell Park Cancer Institute, Presbyterian Hospital, Cornell University, NewYork–Presbyterian Hospital, New York Hospital Queens, Hôpital Saint-Louis, Université Paris Cité, Istituto Oncologico Romagnolo, Hospital Universitari i Politècnic La Fe, European Institute of Oncology, MD Anderson Cancer Center Madrid, University of Michigan–Ann Arbor, Centre Antoine Lacassagne, Fred Hutch Cancer Center, Centre Hospitalier Universitaire de Toulouse, University Cancer Institute Toulouse Oncopole, University of Eastern Piedmont Amadeo Avogadro, Cleveland ClinicA Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
